scholarly journals Impact of Rotavirus Vaccine on Premature Infants

2014 ◽  
Vol 21 (10) ◽  
pp. 1404-1409 ◽  
Author(s):  
Jean-Michel Roué ◽  
Emmanuel Nowak ◽  
Grégoire Le Gal ◽  
Thomas Lemaitre ◽  
Emmanuel Oger ◽  
...  
Keyword(s):  
Premature Infants ◽  
Vaccine Coverage ◽  
Vaccination Campaign ◽  
University Hospital ◽  
Vaccination Program ◽  
National Study ◽  
Rotavirus Vaccine ◽  
Term Infants ◽  
Rotavirus Diarrhea ◽  
The Impact

ABSTRACTInfants born preterm are at a higher risk of complications and hospitalization in cases of rotavirus diarrhea than children born at term. We evaluated the impact of a rotavirus vaccination campaign (May 2007 to May 2010) on hospitalizations for rotavirus gastroenteritis in a population of children under 3 years old born prematurely (before 37 weeks of gestation) in the Brest University Hospital birth zone. Active surveillance from 2002 to 2006 and a prospective collection of hospitalizations for rotavirus diarrhea were initiated in the pediatric units of Brest University Hospital until May 2010. Numbers of hospitalizations for rotavirus diarrhea among the population of children born prematurely, before and after the start of the vaccination program, were compared using a Poisson regression model controlling for epidemic-to-epidemic variation. A total of 217 premature infants were vaccinated from 2007 to 2010. Vaccine coverage for a complete course of three doses was 41.9%. The vaccine safety in premature infants was similar to that in term infants. The vaccination program led to a division by a factor of 2.6 (95% confidence interval [CI], 1.3 to 5.2) in the number of hospitalizations for rotavirus diarrhea during the first two epidemic seasons following vaccine introduction and by a factor of 11 (95% CI, 3.5 to 34.8) during the third season. We observed significant effectiveness of the pentavalent rotavirus vaccine on the number of hospitalizations in a population of prematurely born infants younger than 3 years of age. A multicenter national study would provide better assessment of this impact. (This study [Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France (IVANHOE)] has been registered at ClinicalTrials.gov under registration no. NCT00740935.)

scholarly journals Diarrheal Diseases Hospitalization in Yemen before and after Rotavirus Vaccination

Scientifica ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Mohammed Amood AL-Kamarany ◽  
Lina Al-Areqi ◽  
Abulatif Mujally ◽  
Fawzya Alkarshy ◽  
Arwa Nasser ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
Rotavirus Vaccine ◽  
Diarrheal Diseases ◽  
Predominant Genotype ◽  
Fecal Samples ◽  
Vaccine Introduction ◽  
Rotavirus Vaccination ◽  
Before And After ◽  
Rotavirus Diarrhea ◽  
The Impact

The study aims to assess the impact of rotavirus vaccine introduction on diarrheal diseases hospitalization and to identify the rotavirus genotypes most prevalent before and after vaccine introduction among children ≤ 5 years of age. Rotarix™® rotavirus vaccine is currently licensed for infants in Yemen and was introduced in 2012. The vaccination course consists of two doses. The first dose is administrated at 6 weeks of age and the second dose is completed by 10 weeks. Based on a longitudinal observational study, we assessed the impact of vaccination on rotavirus hospitalization before and after vaccination among children ≤ 5 years of age at the Yemeni-Swedish Hospital (YSH) in Taiz, Yemen. Prevaccination covered January 2009–July 2012 during which 2335 fecal samples were collected from children ≤ 5 years old. Postvaccination covered January 2013–December 2014 during which 1114 fecal samples were collected. Rotavirus was detected by Enzyme Linkage Immunosorbent Assay (ELISA). The incidence ofrotavirushospitalization decreased from 43.79% in 2009 to 10.54% in 2014. Hospitalization due to rotavirus diarrhea was reduced by 75.93%. Vaccine coverage increased from 23% in 2012 to 72% in 2014. Also, the results showed that the most predominant genotypes in prevaccination period were G2P[4] (55.0%), followed by G1P[8] (15.0%), while in postvaccination period G1P[8] (31%) was the predominant genotype, followed by G9P[8] (27.5%). In conclusion, rotavirus vaccination in Yemen resulted in sharp reduction in diarrheal hospitalization. A successful rotavirus vaccination program in Yemen will rely upon efficient vaccine delivery systems and sustained vaccine efficacy against diverse and evolving rotavirus strains.

Impact of Monovalent Rotavirus Vaccine on Rotavirus Hospitalizations among Children Younger Than 5 Years of Age in the Ouest and Artibonite Departments, Haiti, 2013 to 2019

2021 ◽  
Author(s):  
Anne-Marie Desormeaux ◽  
Eleanor Burnett ◽  
Gérard Joseph ◽  
Mentor Ali Ber Lucien ◽  
Negar Aliabadi ◽  
...  
Keyword(s):  
Negative Binomial ◽  
Hospital Admissions ◽  
Absolute Number ◽  
Sensitivity Analyses ◽  
Rotavirus Vaccine ◽  
Vaccine Introduction ◽  
Rotavirus Vaccination ◽  
Before And After ◽  
Rotavirus Diarrhea ◽  
The Impact

Rotavirus is responsible for 26% of diarrheal deaths in Latin America and the Caribbean. Haiti introduced the monovalent rotavirus vaccine in April 2014. The objective of this analysis is to describe the impact of the rotavirus vaccine on hospitalizations among Haitian children younger than 5 years old during the first 5 years after introduction. This analysis includes all children with diarrhea who were enrolled as part of a sentinel surveillance system at two hospitals from May 2013 to April 2019. We compare the proportion of rotavirus-positive specimens in each post-vaccine introduction year to the pre-vaccine period. To account for the potential dilution of the proportion of rotavirus-positive specimens from a waning cholera outbreak, we also analyzed annual trends in the absolute number of positive stools, fit a two-component finite-mixture model to the negative specimens, and fit a negative binomial time series model to the pre-vaccine rotavirus-positive specimens to predict the number of rotavirus diarrhea hospital admissions in the absence of rotavirus vaccination. The overall percentage of rotavirus-positive specimens declined by 22% the first year after introduction, increased by 17% the second year, and declined by 33% to 50% the subsequent 3 years. All sensitivity analyses confirmed an overall decline. We observed a clear annual rotavirus seasonality before and after vaccine introduction, with the greatest activity in December through April, and a biennial pattern, with high sharp peaks and flatter longer periods of increased rotavirus activity in alternating years, consistent with suboptimal vaccination coverage. Overall, our study shows evidence that the introduction of the rotavirus vaccine reduced the burden of severe rotavirus diarrhea.

Use Of A Mobile Cart Influenza Program For Vaccination Of Hospital Employees

2004 ◽  
Vol 25 (11) ◽  
pp. 918-922 ◽  
Author(s):  
Catherine Sartor ◽  
Herve Tissot-Dupont ◽  
Christine Zandotti ◽  
Francoise Martin ◽  
Pierre Roques ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Vaccination Rate ◽  
Associate Professor ◽  
University Hospital ◽  
Vaccination Program ◽  
Vaccination Rates ◽  
Vaccination Acceptance ◽  
The Impact ◽  
Haenszel Test

AbstractObjective:Rates of annual influenza vaccination of healthcare workers (HCWs) remained low in our university hospital. This study was conducted to evaluate the impact of a mobile cart influenza vaccination program on HCW vaccination.Methods:From 2000 to 2002, the employee health service continued its annual influenza vaccination program and the mobile cart program was implemented throughout the institution. This program offered influenza vaccination to all employees directly on the units. Each employee completed a questionnaire. Vaccination rates were analyzed using the Mantel–Haenszel test.Results:The program proposed vaccination to 50% to 56% of the employees. Among the nonvaccinated employees, 52% to 53% agreed to be vaccinated. The compliance with vaccination varied from 61% to 77% among physicians and medical students and from 38% to 55% among nurses and other employees. Vaccination of the chief or associate professor of the unit was associated with a higher vaccination rate of the medical staff (P < .01). Altogether, the vaccination program led to an increase in influenza vaccination among employees from 6% in 1998 and 7% in 1999 before the mobile cart program to 32% in 2000, 35% in 2001, and 32% in 2002 (P < .001).Conclusions:The mobile cart program was associated with a significantly increased vaccination acceptance. Our study was able to identify HCW groups for which the mobile cart was effective and highlight the role of the unit head in its success.

scholarly journals Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh

2019 ◽  
Vol 69 (12) ◽  
pp. 2059-2070 ◽  
Author(s):  
Lauren M Schwartz ◽  
K Zaman ◽  
Md Yunus ◽  
Ahasan-ul H Basunia ◽  
Abu Syed Golam Faruque ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
Controlled Trial ◽  
Population Level ◽  
Diarrhoeal Disease ◽  
Incidence Rates ◽  
Service Area ◽  
Rotavirus Vaccine ◽  
Rotavirus Vaccines ◽  
Time Period ◽  
The Impact

Abstract Background Following the conclusion of a human rotavirus vaccine (HRV) cluster-randomized, controlled trial (CRT) in Matlab, Bangladesh, HRV was included in Matlab’s routine immunization program. We describe the population-level impact of programmatic rotavirus vaccination in Bangladesh in children <2 years of age. Methods Interrupted time series were used to estimate the impact of HRV introduction. We used diarrheal surveillance collected between 2000 and 2014 within the 2 service delivery areas (International Centre for Diarrhoeal Disease Research, Bangladesh [icddr,b] service area [ISA] and government service area [GSA]) of the Matlab Health and Demographic Surveillance System, administered by icddr,b. Age group–specific incidence rates were calculated for both rotavirus-positive (RV+) and rotavirus-negative (RV–) diarrhea diagnoses of any severity presenting to the hospital. We used 2 models to assess the impact within each service area: Model 1 used the pre-vaccine time period in all villages (HRV– and control-only) and Model 2 combined the pre-vaccine time period and the CRT time period, using outcomes from control-only villages. Results Both models demonstrated a downward trend in RV+ diarrheal incidences in the ISA villages during 3.5 years of routine HRV use, though only Model 2 was statistically significant. Significant impacts of HRV on RV+ diarrhea incidences in GSA villages were not observed in either model. Differences in population-level impacts between the 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the hospital. Conclusions This study provides initial evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab, Bangladesh. Further studies are needed of the rotavirus vaccine impact after the nationwide introduction in Bangladesh.

scholarly journals Possible Impact of Wide-scale Vaccination Against Serogroup B Neisseria Meningitidis on Gonorrhea Incidence Rates in One Region of Quebec, Canada

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S734-S735 ◽  
Author(s):  
Jean Longtin ◽  
Rejean Dion ◽  
Marc Simard ◽  
Jean-Francois Betala Belinga ◽  
Yves Longtin ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Vaccine Coverage ◽  
Vaccination Campaign ◽  
Age Groups ◽  
Incidence Rates ◽  
Study Objective ◽  
Grant Recipient ◽  
Invasive Infections ◽  
Wide Scale ◽  
The Impact

Abstract Background Owing to a persistent increase of serogroup B Neisseria meningitidis (Nm) invasive infections in the Saguenay-Lac-Saint-Jean (SLSJ) region of the province of Quebec (Canada) since 2006, a wide-scale vaccination campaign of individuals aged 6 months to 20 years was conducted between May and December 2014 using the 4-component protein-based meningococcus serogroup B vaccine (4CMenB). Components of this vaccine have shown to potentially cross-react with Neisseria gonorrhoeae (Ng). The study objective was to assess the impact of the vaccination campaign on Ng incidence rate (IR). Methods Ng cases notified to public health authorities during prevaccination period (January 2006 to June 2014) and postvaccination period (July 2014 to June 2017) were analyzed. The impact of this mass campaign was estimated by a Poisson regression model, including the year (11 July–June categories), age (14–20 vs. 21 years and older), and the intervention (0 by default and 1 in those 14–20 years in the period of July 2014 to June 2017). Results Overall vaccine coverage was 82% in the target group. A total of 231 Ng cases were reported among persons 14 years and older (IR: 8.4/100,000 person-years) of the SLSJ region from January 2006 to June 2017. A decrease in the Ng number of cases and IR among individuals 14–20 years was observed during the post-vaccination period whereas it increased in those 21 years and older (figure). Estimate of vaccination impact was an Ng risk reduction of 59% (95% CI: −22% to 84%; P = 0.1). During the same period, Chlamydia trachomatis (Ct) infections increased among persons of both age groups in the SLSJ region. Conclusion Although the estimate of the impact of the campaign was not statistically significant, possibly due to limited size of the study population and the low incidence of the disease, it is congruent with results of a case–control study in New Zealand showing an OMV-MeNZB vaccine effectiveness of 31%. A higher effectiveness of 4CMenB is a plausible hypothesis as three additional proteins also found in Ng are included in the vaccine used in the SLSJ region. The results of this ecologic study suggest cross-protection of 4CMenB vaccine against Ng infections. Further studies on this topic are warranted. Disclosures P. De Wals, GlaxoSmithKline: Grant Investigator and Scientific Advisor, Grant recipient and travel expenses. Pfizer: Grant Investigator and Scientific Advisor, Grant recipient and travel expenses. Sanofi-Pasteur: Grant Investigator and Scientific Advisor, Grant recipient and travel expenses. Novartis: Grant Investigator and Scientific Advisor, Grant recipient and travel expenses.

scholarly journals Differences in Neurocognitive Abilities in Premature and Full-term Infants at 5 Months of Age

2018 ◽  
Author(s):  
S Kiselev ◽  
O Lvova ◽  
E Suleymanova
Keyword(s):  
Premature Infants ◽  
Receptive Language ◽  
Full Term ◽  
Fine Motor ◽  
Term Infants ◽  
Neurocognitive Development ◽  
Neurocognitive Functions ◽  
Toddler Development ◽  
The Impact ◽  
Bayley Scales

It is known that prematurity is a risk for neurodevelopmental disorders. Most of the studies were dedicated to those children who have reached the preschool and primary school age. However, the impact of prematurity on neurocognitive functions in the early stages of development is not investigated thoroughly. The aim of thisresearch was to reveal the differences in neurocognitive development in premature (24 babies) and gender-matched healthy mature full-term infants (31 participants) at 5 months of age. The gestational age of preterm children was between 29 and 35 weeks. The Bayley Scales of Infant and Toddler Development (3rd Edition) were used to evaluate the neurocognitive abilities in children. The one-way ANOVA has revealedthat premature infants at 5 months of corrected age performed significantly (p ≤ 0.05) more poorly than the full-term infants on cognitive scale, receptive language, gross and fine motor. No significant differences (p ≤.05) were found between preterm and full-term children on expressive language. In view of the obtained results, itcan be assumed that the prematurity has specific (not global) negative effect on neurocognitive development at 5 months of age. Keywords: premature infants, neurocognitive development, Bayley Scales of Infant and Toddler Development (3rd Edition)

scholarly journals Impact of Extending the Timing of Maternal Pertussis Vaccination on Hospitalized Infant Pertussis in England, 2014–2018

2020 ◽  
Author(s):  
Elise Tessier ◽  
Helen Campbell ◽  
Sonia Ribeiro ◽  
Norman K Fry ◽  
Colin Brown ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Policy Change ◽  
Vaccine Coverage ◽  
Length Of Hospital Stay ◽  
Term Infants ◽  
Hospital Stays ◽  
Clinical Records ◽  
The Impact ◽  
Median Hospital ◽  
Optimal Window

Abstract Background In October 2012, a maternal pertussis vaccination program was introduced in England for women between 28 and 32 weeks of pregnancy. In April 2016, the recommended optimal window was extended to 20–32 weeks to improve vaccine coverage and protect preterm infants. This study assesses the impact of offering maternal pertussis vaccination earlier in pregnancy on hospitalized infant pertussis cases. Methods Hospitalized pertussis cases ≤60 days old in England were extracted from Hospital Episode Statistics pre- and post-policy change. Data were linked to laboratory-confirmed cases, and clinical records were reviewed where cases were not matched. Maternal vaccine status of identified cases was established. Median hospital duration was calculated, and a competing risk survival analysis was undertaken to assess multiple factors. Results A total of 201 cases were included in the analysis. Of the 151 cases with reported gestational age, the number of hospitalizations among full-term infants was 60 cases pre-policy and 62 cases post-policy, respectively, while preterm cases declined from 20 to 9 (P = .06). Length of hospital stay did not differ significantly after the policy change. Significantly longer hospital stays were seen in cases aged 0–4 weeks (median of 3 more days than infants aged 5–8 weeks), premature infants (median of 4 more days than term infants), and cases with coinfections (median of 1 more day than those without coinfection). Conclusions The number of preterm infants hospitalized with pertussis in England was halved after the policy change and preterm infants were no longer overrepresented among hospitalized cases.

scholarly journals Level and Factors Associated with the Satisfaction of Teaching Staff with the COVID-19 Vaccination Program.

2021 ◽  
Author(s):  
Natividad Algado-Selles ◽  
Pablo Chico-Sánchez ◽  
Paula Gras-Valentí ◽  
Natali Juliet Jiménez-Sepúlveda ◽  
Isel Lilibeth Gómez-Sotero ◽  
...  
Keyword(s):  
Vaccination Coverage ◽  
User Satisfaction ◽  
School Personnel ◽  
University Hospital ◽  
Vaccination Program ◽  
Teaching Staff ◽  
Cross Sectional ◽  
Vaccination Programs ◽  
Level Of Satisfaction ◽  
The Impact

Abstract Background The impact of COVID-19 triggered an unparalleled effort towards the development of a vaccine given that vaccination is currently the most important strategy available for controlling the pandemic. Achieving high levels of vaccination coverage is key to this approach, and requires knowledge of user satisfaction levels. Thus, the objective of this work was to determine the levels of satisfaction with the COVID-19 vaccination program among vaccinated school workers.MethodsThis was a cross-sectional study which included the staff from educational centres invited for vaccination over 4 days at the Hospital General University Hospital of Alicante. The survey included sociodemographic variables, 13 questions on satisfaction with the vaccination program, and one open question for further suggestions. Satisfaction was calculated globally for each question and specifically by employing Student t-tests; the association between each variable and a high level of satisfaction was analysed with Chi-squared tests. Results Of 9,869 professionals invited, 9,261 attended the appointment; 5,756 were offered the possibility of participating in this survey and 2,989 (51.9%) accepted. The highest overall scores were assigned to the treatment patients received at the ‘registration point’ and the care they received from nurses during the vaccination. The aspect for which the lowest levels of satisfaction were registered was for the information received prior to vaccination. Sex and place of work were significantly associated with a high degree of satisfaction.Conclusions Understanding people’s perception of vaccination programs is essential to implementing improvements and to increase vaccination coverage. The level of satisfaction among school personnel was remarkably high, especially in relation to the treatment and attention they received at different points during the vaccination care circuit.

scholarly journals Modeling the impact of COVID-19 vaccination in Lebanon: A call to speed-up vaccine roll out

2021 ◽  
Author(s):  
Ghina R Mumtaz ◽  
Fadi El-Jardali ◽  
Mathilda Jabbour ◽  
Aya Harb ◽  
Laith J Abu-Raddad ◽  
...  
Keyword(s):  
Vaccine Coverage ◽  
Vaccination Campaign ◽  
Scale Up ◽  
High Coverage ◽  
Social Distancing ◽  
Epidemic Curve ◽  
Limited Health ◽  
Care Capacity ◽  
The Impact ◽  
Roll Out

Background: Amidst a very difficult economic and political situation, and after a large first SARS-CoV-2 wave near the end of 2020, Lebanon launched its vaccination campaign on 14 February 2021. To date, only 6.7% of the population have received at least one dose of the vaccine, raising serious concerns over the speed of vaccine roll-out and its impact in the event of a future surge. Objective: Using mathematical modeling, we assessed the short-term impact (by end of 2021) of various vaccine roll-out scenarios on SARS-CoV-2 epidemic course in Lebanon. Results: At current immunity levels in the population, estimated by the model at 40% on 15 April 2021, a large epidemic wave is predicted if all social distancing restrictions are gradually eased and variants of concern are introduced. Reaching 80% vaccine coverage by end of 2021 will flatten the epidemic curve and will result in a 37% and 34% decrease in the peak daily numbers of severe/critical disease cases and deaths, respectively; while reaching intermediate coverage of 40% will result in only 10-11% decrease in each. Reaching 80% coverage by end of 2021 will avert 3 times more hospitalizations and deaths over the course of this year compared with 40% coverage. Impact of vaccination was substantially enhanced with rapid scale-up. Reaching 80% vaccine coverage by August would prevent twice as many severe/critical disease cases and deaths than if it were reached by December. Finally, a longer duration over which restrictions are eased resulted in a more favorable impact of vaccination. Conclusion: For vaccination to have an impact on the predicted epidemic course and associated disease burden in Lebanon, vaccination has to be rapid and reach high coverage (at least 70%), while sustaining social distancing measures during roll-out. At current vaccination pace, this is unlikely to be achieved. Concerted efforts need to be put to overcome local challenges and substantially scale up vaccination to avoid a surge that the country, with its multiple crises and limited health-care capacity, is largely unprepared for.

Sign in / Sign up

Export Citation Format

Share Document